Sleeping Sickness
9
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
Screen and Treat Implementation for HAT Control
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2